STC2 and cervical cancer: Additionally, STC2, which has been implicated in drug resistance in cervical cancer (30), was in the following four drug resistance gene profiles: paclitaxel in the HR+HER2- subtype, paclitaxel with ganetespib in the HR+HER2- subtype, paclitaxel with pertuzumab and trastuzumab in the HR+HER2+ subtype, and paclitaxel with trastuzumab in the HR+HER2+ subtype.